Search

Your search keyword '"Smith, Jaclyn A."' showing total 998 results
Start Over Author "Smith, Jaclyn A."
998 results on '"Smith, Jaclyn A."'

1. Tissue spaces are reservoirs of antigenic diversity for Trypanosoma brucei

Author

Beaver, Alexander K., Keneskhanova, Zhibek, Cosentino, Raúl O., Weiss, Brian L., Awuoche, Erick O., Smallenberger, Gretchen M., Buenconsejo, Gracyn Y., Crilly, Nathan P., Smith, Jaclyn E., Hakim, Jill M. C., Zhang, Bailin, Bobb, Bryce, Rijo-Ferreira, Filipa, Figueiredo, Luisa M., Aksoy, Serap, Siegel, T. Nicolai, and Mugnier, Monica R.

Published
2024
Full Text
View/download PDF

8. Functional Collection Programming with Semi-Ring Dictionaries

Author

Shaikhha, Amir, Huot, Mathieu, Smith, Jaclyn, and Olteanu, Dan

Subjects
Computer Science - Programming Languages, Computer Science - Databases, Computer Science - Machine Learning
Abstract

This paper introduces semi-ring dictionaries, a powerful class of compositional and purely functional collections that subsume other collection types such as sets, multisets, arrays, vectors, and matrices. We developed SDQL, a statically typed language that can express relational algebra with aggregations, linear algebra, and functional collections over data such as relations and matrices using semi-ring dictionaries. Furthermore, thanks to the algebraic structure behind these dictionaries, SDQL unifies a wide range of optimizations commonly used in databases (DB) and linear algebra (LA). As a result, SDQL enables efficient processing of hybrid DB and LA workloads, by putting together optimizations that are otherwise confined to either DB systems or LA frameworks. We show experimentally that a handful of DB and LA workloads can take advantage of the SDQL language and optimizations. SDQL can be competitive with or outperforms a host of systems that are state of the art in their own domain: in-memory DB systems Typer and Tectorwise for (flat, not nested) relational data; SciPy for LA workloads; sparse tensor compiler taco; the Trance nested relational engine; and the in-database machine learning engines LMFAO and Morpheus for hybrid DB/LA workloads over relational data.

Published
2021

11. Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study

Author

Dicpinigaitis, Peter V., Morice, Alyn H., Smith, Jaclyn A., Sher, Mandel R., Vaezi, Michael, Guilleminault, Laurent, and Niimi, Akio

Subjects
Merck & Company Inc., Bayer AG, Kyorin Pharmaceutical Company Ltd., Novartis AG, AstraZeneca PLC, Respiratory agents -- Analysis, Liver -- Analysis, Clinical trials -- Analysis, Pharmaceutical industry -- Analysis, Health
Abstract

Introduction The PAGANINI study evaluated the efficacy and safety of the selective P2X3 antagonist eliapixant in patients with refractory chronic cough (RCC). Methods PAGANINI was a randomized, double-blind, parallel-group, placebo-controlled, multicenter, dose-finding, phase 2b study. Adults with RCC lasting [greater than or equal to] 12 months and cough severity [greater than or equal to] 40 mm on a visual analog scale at screening were enrolled. Participants were randomized 1:1:1:1 to twice-daily 25 mg, 75 mg, or 150 mg oral eliapixant or placebo for 12 weeks. The primary endpoint was change from baseline in 24-h cough count after 12 weeks of intervention. Results Overall, 310 participants were randomized to twice-daily eliapixant 25 mg (n = 75), 75 mg (n = 78), 150 mg (n = 80), or placebo (n = 77). A statistically significant dose-response signal with eliapixant was detected for the primary endpoint (all dose-response models, adjusted p < 0.1; one-sided). Adverse events (AEs) were reported in 39 (51%) participants with placebo and 43-51 (57-65%) participants receiving eliapixant. The most common AE was dysgeusia, occurring in 1% (n = 1) of the placebo group and 1-16% (n = 1-13) of the eliapixant groups in a dose-related manner. One case of a moderate drug-induced liver injury occurred in a participant receiving 150 mg twice-daily eliapixant. Conclusion Eliapixant demonstrated efficacy and a favorable taste tolerability profile in RCC. However, a drug-induced liver injury contributed to intensified liver monitoring in clinical trials with eliapixant and discontinuation of the entire development program in all indications by Bayer AG. Trial Registration ClinicalTrials.gov identifier NCT04562155; registered September 18, 2020., Author(s): Peter V. Dicpinigaitis [sup.1], Alyn H. Morice [sup.2], Jaclyn A. Smith [sup.3], Mandel R. Sher [sup.4], Michael Vaezi [sup.5], Laurent Guilleminault [sup.6] [sup.7], Akio Niimi [sup.8], Kerstin Gude [sup.9], [...]

Published
2023
Full Text
View/download PDF

12. Scalable Querying of Nested Data

Author

Smith, Jaclyn, Benedikt, Michael, Nikolic, Milos, and Shaikhha, Amir

Subjects
Computer Science - Databases, H.2.3, H.2.4
Abstract

While large-scale distributed data processing platforms have become an attractive target for query processing, these systems are problematic for applications that deal with nested collections. Programmers are forced either to perform non-trivial translations of collection programs or to employ automated flattening procedures, both of which lead to performance problems. These challenges only worsen for nested collections with skewed cardinalities, where both handcrafted rewriting and automated flattening are unable to enforce load balancing across partitions. In this work, we propose a framework that translates a program manipulating nested collections into a set of semantically equivalent shredded queries that can be efficiently evaluated. The framework employs a combination of query compilation techniques, an efficient data representation for nested collections, and automated skew-handling. We provide an extensive experimental evaluation, demonstrating significant improvements provided by the framework in diverse scenarios for nested collection programs.

Published
2020

14. Declarative nested data transformations at scale and biomedical applications

Author

Smith, Jaclyn and Benedikt, Michael

Subjects
Genomics, Data processing, Query languages (Computer science), Big data
Abstract

While large-scale distributed data processing platforms have become an attractive tar- get for query processing, these systems are problematic for applications that deal with nested collections. Programmers are forced either to perform non-trivial translations of collection programs or to employ automated flattening procedures, both of which lead to performance problems. These challenges only worsen for nested collections with skewed cardinalities, where both handcrafted rewriting and automated flattening are unable to enforce load balancing across partitions. In this work, the TraNCE compilation framework is proposed that translates a program manipulating nested collections into a set of semantically equivalent shredded queries that can be efficiently evaluated. The framework employs a combination of query compilation techniques, an efficient data representation for nested collections, and automated skew-handling. Biomedical case studies are presented that outline research and clinical applications for the platform, including data integration support for building feature sets for classification. An extensive experimental evaluation is provided using both synthetic and real-world dataset from the biomedical domain. The evaluation shows that the system is capable of outperforming the common alternative, based on "flattening" complex data structures, and runs efficiently when alternative approaches are unable to perform at all.

Published
2021

15. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough

Author

McGarvey, Lorcan, Smith, Jaclyn A., Morice, Alyn, Birring, Surinder S., Chung, Kian Fan, Dicpinigaitis, Peter V., and Niimi, Akio

Subjects
Merck & Company Inc. -- Product development, Shionogi & Company Ltd. -- Product development, Bayer AG -- Product development, Medical research, Medicine, Experimental, Patient compliance -- Research, Clinical trials -- Research, Pharmaceutical industry -- Product development, Health, Cleveland Clinic
Abstract

Introduction To determine the optimal dose of sivopixant, a highly selective P2X3 receptor antagonist, for refractory or unexplained chronic cough (RCC/UCC). Methods In this phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial, patients received sivopixant 50, 150, or 300 mg or placebo once daily for 4 weeks. The primary endpoint was a change from baseline in 24-h cough frequency (coughs/h) with sivopixant vs placebo. Results Overall, 390/406 randomized patients completed the study. Placebo-adjusted changes in hourly cough count over 24 h were 13.17% (P = 0.3532), - 1.77% (P = 0.8935), and - 12.47% (P = 0.3241) and in cough severity (visual analog scale) were 1.75 mm (P = 0.5854), - 1.21 mm (P = 0.7056), and - 6.55 mm (P = 0.0433) with sivopixant 50, 150, and 300 mg, respectively. Placebo-adjusted changes from baseline in Leicester Cough Questionnaire total scores were - 0.37 (P = 0.4207), - 0.07 (P = 0.8806), and 0.69 (P = 0.1473) with sivopixant 50, 150, and 300 mg, respectively. Additionally, 61.3%, 78.3%, 86.8%, and 71.4% of patients receiving sivopixant 50, 150, and 300 mg and placebo, respectively, reported any improvements in Patient Global Impression of Change. The incidence of treatment-emergent adverse events (TEAEs) was 25.7%, 32.0%, 49.0%, and 20.6% in sivopixant 50, 150, and 300 mg and placebo groups, respectively; all TEAEs in the sivopixant group were mild-to-moderate. Conclusion Sivopixant did not demonstrate a statistically significant difference vs placebo in change from baseline in 24-h cough frequency. The dose of 300 mg has potential for RCC/UCC, showing the greatest improvements in cough frequency and patient-reported outcomes and dose-related mild to moderate reversible taste disturbance, although further trials are needed. Clinical Trial Registration ClinicalTrials.gov identifier NCT04110054; registered September 26, 2019., Author(s): Lorcan McGarvey [sup.1], Jaclyn A. Smith [sup.2], Alyn Morice [sup.3], Surinder S. Birring [sup.4], Kian Fan Chung [sup.5], Peter V. Dicpinigaitis [sup.6], Akio Niimi [sup.7], Michael S. Benninger [sup.8], [...]

Published
2023
Full Text
View/download PDF

21. Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups

Author

Smith, Jaclyn A., Birring, Surinder S., Dicpinigaitis, Peter V., McGarvey, Lorcan P., Morice, Alyn H., Pavord, Ian D., and Satia, Imran

Subjects
Bayer HealthCare Pharmaceuticals, Pharmaceutical industry -- Analysis, Health
Abstract

Introduction In phase 3 trials (COUGH-1/COUGH-2), gefapixant 45 mg twice daily significantly reduced 24-h cough frequency vs placebo in refractory or unexplained chronic cough (RCC or UCC). Methods Here, the efficacy of gefapixant 45 mg vs placebo was evaluated across COUGH-1/COUGH-2 in predefined subgroups based on sex, region, age, cough duration, cough severity, cough frequency, and diagnosis (RCC, UCC). Awake cough frequency reductions at Week 12 and LCQ response rates (i.e., [greater than or equal to] 1.3-point improvement) at Week 24 were assessed. Results Among 1360 participants analyzed, gefapixant 45 mg resulted in consistent awake cough frequency reductions overall and across predefined subgroups at Week 12. Gefapixant also resulted in improved LCQ scores across subgroups at Week 24; [greater than or equal to] 70% of participants in each subgroup treated with gefapixant 45 mg had an LCQ response. Conclusion These data suggest gefapixant 45 mg provides consistent objective and subjective efficacy across subgroups of individuals with RCC or UCC., Author(s): Jaclyn A. Smith [sup.1], Surinder S. Birring [sup.2], Peter V. Dicpinigaitis [sup.3], Lorcan P. McGarvey [sup.4], Alyn H. Morice [sup.5], Ian D. Pavord [sup.6], Imran Satia [sup.7] [sup.8], Stuart [...]

Published
2022
Full Text
View/download PDF

25. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

Author

Smith, Jaclyn, McGarvey, Lorcan, Birring, Surinder, Hull, James, Carr, Warner W, Goldsobel, Alan B, Gross, Gary N, Holcomb, John R, Hussain, Iftikhar, Sher, Mandel, Spangenthal, Selwyn, Storms, William, Morice, Alyn, Elkayam, David, Steven, Gary C, Krainson, James, Fakih, Faisal Alfonso, Matz, Jonathan, Brooks, Gregory Daniel, Casale, Thomas, Berman, Gary D, Condemi, John J, Greos, Leon S, Gogate, Shaila U, Sher, Ellen R, Friesen, Jason H, Schenkel, Eric J, Bernstein, David Isaac, Corren, Jonathan, Sundar, Krishna, Gotfried, Mark H, Montanaro, Anthony, Lumry, William R, Amar, Niran J, Kaplan, Michael S, Prenner, Bruce M, Murphy, Thomas R, Good, James S, Parker, Sean, Harrison, Tim, Pavord, Ian, Brightling, Christopher, Djukanovic, Ratko, McQuaid, Douglas, Denenberg, Michael, Ettinger, Neil A, Iyer, Vivek, Smith, Jaclyn A, Kitt, Michael M, Morice, Alyn H, Birring, Surinder S, McGarvey, Lorcan P, Sher, Mandel R, Li, Yu-Ping, Wu, Wen-Chi, Xu, Zhi Jin, Muccino, David R, and Ford, Anthony P

Published
2020
Full Text
View/download PDF

27. Persistence of Microcystin in Three Agricultural Ponds in Georgia, USA.

Author

Smith, Jaclyn E., Widmer, James A., Wolny, Jennifer L., Dunn, Laurel L., Stocker, Matthew D., Hill, Robert L., Pisani, Oliva, Coffin, Alisa W., and Pachepsky, Yakov

Subjects
*LAKES, *CYANOBACTERIAL toxins, *WATER quality monitoring, *BODIES of water, *AGRICULTURE, *PONDS
Abstract

Cyanobacteria and their toxins can have multiple effects on agricultural productivity and water bodies. Cyanotoxins can be transported to nearby crops and fields during irrigation and may pose a risk to animal health through water sources. Spatial and temporal variations in cyanotoxin concentrations have been reported for large freshwater sources such as lakes and reservoirs, but there are fewer studies on smaller agricultural surface water bodies. To determine whether spatiotemporal patterns of the cyanotoxin microcystin occurred in agricultural waters used for crop irrigation and livestock watering, three agricultural ponds on working farms in Georgia, USA, were sampled monthly within a fixed spatial grid over a 17-month period. Microcystin concentrations, which ranged between 0.04 and 743.75 ppb, were determined using microcystin–ADDA ELISA kits. Temporal stability was assessed using mean relative differences between microcystin concentrations at each location and averaged concentrations across ponds on each sampling date. There were locations or zones in all three ponds that were consistently higher or lower than the average daily microcystin concentrations throughout the year, with the highest microcystin concentrations occurring in winter. Additionally, microcystin patterns were strongly correlated with the patterns of chlorophyll, phycocyanin, and turbidity. The results of this work showed that consistent spatiotemporal patterns in cyanotoxins can occur in produce irrigation and livestock watering ponds, and this should be accounted for when developing agricultural water monitoring programs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials

Author

McGarvey, Lorcan P, Birring, Surinder S, Morice, Alyn H, Dicpinigaitis, Peter V, Pavord, Ian D, Schelfhout, Jonathan, Nguyen, Allison Martin, Li, Qing, Tzontcheva, Anjela, Iskold, Beata, Green, Stuart A, Rosa, Carmen La, Muccino, David R, and Smith, Jaclyn A

Published
2022
Full Text
View/download PDF

34. Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant

Author

Morice, Alyn H., Birring, Surinder S., Smith, Jaclyn A., McGarvey, Lorcan P., Schelfhout, Jonathan, Martin Nguyen, Allison, and Xu, Zhi Jin

Subjects
Merck & Company Inc., Bayer AG, Merck Sharp & Dohme Corp., Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Respiratory agents -- Health aspects, Comorbidity -- Health aspects, Gastroesophageal reflux -- Health aspects, Antacids -- Health aspects, Antihistamines -- Health aspects, Clinical trials -- Health aspects, Pharmaceutical industry -- Health aspects, Asthma -- Health aspects, Health
Abstract

Purpose This analysis assesses clinical characteristics of patients with refractory chronic cough (RCC) or unexplained chronic cough (UCC) enrolled in a phase 2 study to better understand this patient population. Methods Patients with RCC/UCC lasting for [greater than or equal to] 1 year and cough severity visual analog scale (VAS) score of > 40 mm at screening were eligible. Demographics, clinical characteristics, and medical history were collected at baseline. Cough-related measures included cough severity VAS, Cough Severity Diary (CSD), Leicester Cough Questionnaire (LCQ), and a structured cough-trigger questionnaire. Medication history included all medications 30 days before screening and chronic cough treatments within 1 year before screening. Data were summarized using descriptive statistics. Results Patients (N = 253; female, 76%; mean age, 60 years) had severe (mean cough severity VAS, 57.5 mm) and long-lasting (median duration, 11 years) cough. The most burdensome self-reported aspects included psychological and social factors (LCQ) and cough frequency and intensity (CSD). Patient-reported triggers were consistent with cough hypersensitivity (e.g., 95% to 96% reported irritation or tickle in throat). Common reported comorbidities included gastroesophageal reflux disease (GERD; 56%), allergic rhinitis (47%), and asthma (30%); 12% of patients had been diagnosed with all 3 conditions. The most common prior medications included inhaled or oral steroids (21%), antihistamines (15%), and antacids (15%). Conclusion Patients with RCC/UCC had severe, long-lasting, and burdensome cough with clinical features of cough hypersensitivity. Many patients had been diagnosed with GERD, allergic rhinitis, and asthma but had a persistent cough despite treatment of these conditions. Trial registration: ClinicalTrials.gov, NCT02612610; registered November 20, 2015, Author(s): Alyn H. Morice [sup.1], Surinder S. Birring [sup.2], Jaclyn A. Smith [sup.3], Lorcan P. McGarvey [sup.4], Jonathan Schelfhout [sup.5], Allison Martin Nguyen [sup.5], Zhi Jin Xu [sup.5], Wen-Chi Wu [...]

Published
2021
Full Text
View/download PDF

35. Managing Chronic Cough Due to Asthma and NAEB in Adults and Adolescents: CHEST Guideline and Expert Panel Report

Author

Altman, Kenneth W., Azoulay, Elie, Barker, Alan F., Blackhall, Fiona, Bolser, Donald C., Birring, Surinder S., Braman, Sidney S., Brightling, Christopher, Callahan-Lyon, Priscilla, Chang, Anne B., Cowley, Terrie, Davenport, Paul, El Solh, Ali A., Escalante, Patricio, Field, Stephen K., Fisher, Dina, French, Cynthia T., Grant, Cameron, Gibson, Peter, Harding, Susan M., Harnden, Anthony, Hill, Adam T., Irwin, Richard S., Kahrilas, Peter J., Kavanagh, Joanne, Lai, Kefang, Lane, Andrew P., Lilly, Craig, Lown, Mark, Madison, J. Mark, Malesker, Mark A., Mazzone, Stuart, McGarvey, Lorcan, Molasoitis, Alex, Moore, Abigail, Murad, M. Hassan, Narasimhan, Mangala, Oppenheimer, John, Rosen, Mark, Rubin, Bruce, Russell, Richard J., Ryu, Jay H., Singh, Sonal, Smith, Jaclyn, Smith, Maeve P., Tarlo, Susan M., Vertigan, Anne E., Weinberger, Miles, Côté, Andreanne, Boulet, Louis-Philippe, Gibson, Peter G., and Brightling, Christopher E.

Published
2020
Full Text
View/download PDF

36. Acute Cough Due to Acute Bronchitis in Immunocompetent Adult Outpatients: CHEST Expert Panel Report

Author

Adams, Todd M., Altman, Kenneth W., Azoulay, Elie, Barker, Alan F., Blackhall, Fiona, Birring, Surinder S., Bolser, Donald C., Boulet, Louis-Philippe, Braman, Sidney S., Brightling, Christopher, Callahan-Lyon, Priscilla, Chang, Anne B., Cowley, Terrie, Davenport, Paul, El Solh, Ali A., Escalante, Patricio, Field, Stephen K., Fisher, Dina, French, Cynthia T., Grant, Cameron, Harding, Susan M., Harnden, Anthony, Hill, Adam T., Irwin, Richard S., Kahrilas, Peter J., Kavanagh, Joanne, Lai, Kefang, Lilly, Craig, Lown, Mark, Madison, J. Mark, Malesker, Mark A., Mazzone, Stuart, McGarvey, Lorcan, Molasoitis, Alex, Murad, M. Hassan, Narasimhan, Mangala, Newcombe, Peter, Oppenheimer, John, Rosen, Mark, Rubin, Bruce, Russell, Richard J., Ryu, Jay H., Singh, Sonal, Smith, Jaclyn, Smith, Maeve P., Tarlo, Susan M., Vertigan, Anne E., Weinberger, Miles, Ireland, Belinda, and Linder, Jeffrey A.

Published
2020
Full Text
View/download PDF

39. DNA damage drives antigen diversification through mosaic VSG formation inTrypanosoma brucei

Author

Smith, Jaclyn E., primary, Wang, Kevin J., additional, Hakim, Jill M.C., additional, Beaver, Alexander K., additional, Magesh, Aishwarya, additional, Gilligan-Steinberg, Shane D., additional, Zheng, Jessica, additional, So, Jaime, additional, Kennedy, Erin M., additional, Zhang, Bailin, additional, Akin, Elgin Henry, additional, Mwakibete, Lusajo, additional, and Mugnier, Monica R., additional

Published
2024
Full Text
View/download PDF

40. Misconceptions on behavioral cough suppression therapy for pediatric nonspecific cough: A response to Weinberger and Buettner's commentary on Fujiki et al.

Author

Slovarp, Laurie, primary, Jette, Marie, additional, Reynolds, Jane, additional, Gillespie, Amanda I, additional, Barkmeier‐Kraemer, Julie, additional, Sandage, Mary, additional, Smith, Jaclyn, additional, Haines, Jemma, additional, Vertigan, Anne, additional, and Mazzone, Stuart, additional

Published
2024
Full Text
View/download PDF

46. Chronic Cough and Gastroesophageal Reflux in Children: CHEST Guideline and Expert Panel Report

Author

Adams, Todd M., Altman, Kenneth W., Azoulay, Elie, Barker, Alan F., Bolser, Donald C., Birring, Surinder S., Braman, Sidney S., Brightling, Christopher, Callahan-Lyon, Priscilla, Chang, Anne B., Cowley, Terrie, Davenport, Paul, El Solh, Ali A., Escalante, Patricio, Field, Stephen K., Fisher, Dina, French, Cynthia T., Grant, Cameron, Gibson, Peter, Harding, Susan M., Gold, Philip, Harnden, Anthony, Hill, Adam T., Irwin, Richard S., Kahrilas, Peter J., Kavanagh, Joanne, Lai, Kefang, Lim, Kaiser, Madison, J. Mark, Malesker, Mark A., Mazzone, Stuart, McGarvey, Lorcan, Metlay, Joshua P., Molasoitis, Alex, Murad, M. Hassan, Narasimhan, Mangala, Newcombe, Peter, Oppenheimer, John, Rosen, Mark, Rubin, Bruce, Russell, Richard J., Ryu, Jay H., Singh, Sonal, Smith, Jaclyn, Smith, Maeve P., Tarlo, Susan M., Turmel, Julie, Vertigan, Anne E., Weinberger, Miles, Oppenheimer, John J., Kantar, Ahmad, and Rubin, Bruce K.

Published
2019
Full Text
View/download PDF

47. Clinically Diagnosing Pertussis-associated Cough in Adults and Children: CHEST Guideline and Expert Panel Report

Author

Altman, Kenneth W., Azoulay, Elie, Barker, Alan F., Bolser, Donald C., Birring, Surinder S., Blackwell, Fiona, Boulet, Louis-Philippe, Braman, Sidney S., Brightling, Christopher, Callahan-Lyon, Priscilla, Chang, Anne B., Cowley, Terrie, Davenport, Paul, El Solh, Ali A., Escalante, Patricio, Field, Stephen K., Fisher, Dina, French, Cynthia T., Grant, Cameron, Gibson, Peter, Gold, Philip, Harding, Susan M., Harnden, Anthony, Hill, Adam T., Irwin, Richard S., Kahrilas, Peter J., Kavanagh, Joanne, Keogh, Karina A., Lai, Kefang, Lane, Andrew P., Lim, Kaiser, Lown, Mark, Madison, J. Mark, Malesker, Mark A., Mazzone, Stuart, McGarvey, Lorcan, Molasoitis, Alex, Moore, Abigail, Murad, M. Hassan, Narasimhan, Mangala, Newcombe, Peter, Nguyen, Huong Q., Oppenheimer, John, Rosen, Mark, Rubin, Bruce, Russell, Richard J., Ryu, Jay H., Singh, Sonal, Smith, Jaclyn, Smith, Maeve P., Tarlo, Susan M., Vertigan, Anne E., Weinberger, Miles, Grant, Cameron C., and Patel, Sheena

Published
2019
Full Text
View/download PDF

48. Adult Outpatients With Acute Cough Due to Suspected Pneumonia or Influenza: CHEST Guideline and Expert Panel Report

Author

Adams, Todd M., Altman, Kenneth W., Azoulay, Elie, Barker, Alan F., Birring, Surinder S., Blackhall, Fiona, Bolser, Donald C., Boulet, Louis-Philippe, Braman, Sidney S., Brightling, Christopher, Callahan-Lyon, Priscilla, Chang, Anne B., Cowley, Terrie, Davenport, Paul, El Solh, Ali A., Escalante, Patricio, Field, Stephen K., Fisher, Dina, French, Cynthia T., Gibson, Peter, Gold, Philip, Grant, Cameron, Harding, Susan M., Harnden, Anthony, Hill, Adam T., Irwin, Richard S., Kahrilas, Peter J., Kavanagh, Joanne, Keogh, Karina A., Lai, Kefang, Lane, Andrew P., Lim, Kaiser, Madison, J. Mark, Malesker, Mark A., Mazzone, Stuart, McGarvey, Lorcan, Molasoitis, Alex, Moore, Abigail, Murad, M. Hassan, Narasimhan, Mangala, Newcombe, Peter, Nguyen, Huong Q., Oppenheimer, John, Rosen, Mark, Rubin, Bruce, Russell, Richard J., Ryu, Jay H., Singh, Sonal, Smith, Jaclyn, Smith, Maeve P., Tarlo, Susan M., Turmel, Julie, Vertigan, Anne E., Wang, Gang, Weinberger, Miles, Gold, Philip M., Metlay, Joshua P., and Ireland, Belinda

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results